Get access

Factors impacting on quality of life in Parkinson's disease: Results from an international survey

Authors

  • The Global Parkinson's Disease Survey (GPDS) Steering Committee

    1. Essex Neurosciences Unit, Oldchurch Hospital, Romford, Essex, RM7OBE, UK
    Search for more papers by this author
    • GPDS Steering Committee: Prof. Leslie Findley, Essex Neurosciences Unit, UK; Dr. Tobias Eichhorn, Neurologische Klinik der Philipss, Universitaet Marburg, Germany; Assoc. Prof. Aleksandar Janca, Department of Psychiatry, University of Western Australia, Perth, Australia; Dr. Joerg Kazenwadel, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Mrs. Mary Baker MBE, President European Parkinson's Disease Association, London, UK; Dr. Daniela Currie-Gnjesda, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Prof. William Koller, Department of Neurology, University of Miami, Miami, Florida, USA; Prof. Abraham Liebermann, Department of Neurology, National Parkinson Foundation Inc., Miami, Florida, USA; Prof. Yoshikuno Mizuno, Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan; Prof. Ali Rajput, Department of Neurology, University of Saskatchewan, Saskatoon, Canada; Mrs. Sheila Roy, Independent Consultant, UK; Prof. Fabrizio Stocchi, Universita la Sapienza, Dipartimento di Scienze Neurologiche, Roma, Italy; Prof. Eduardo Tolosa, Servicio de Neurologia, Hospital Clinic I Provinical, Barcelona, Spain.


Abstract

Current management guidelines for the treatment of patients with Parkinson's disease (PD) are limited due to the lack of knowledge of factors that influence health-related quality of life (HRQL). To assess the HRQL of people with PD, and to systematically identify and evaluate those factors (other than disease severity and medication, which could have an impact), we undertook a cross-sectional, randomized selection, multicenter international survey of patients with PD, caregivers, and clinicians. Face-to-face interviews were conducted with subjects in six countries. Disease severity, medication, and other factors hypothesized to influence HRQL were assessed using a combination of specially developed questionnaires and validated instruments including the Parkinson's Disease Questionnaire-39 (HRQL), Hoehn and Yahr Stage (disease severity), and Beck's Depression Inventory (BDI; depression). Multiple linear regression models were used to demonstrate whether the factors investigated contribute significantly to HRQL. The results obtained indicated that Hoehn and Yahr stage and medication explained only 17.3% of the variability in HRQL of patients with PD, although both were significant (R2 = 0.173, P < 0.05). Other factors increased the explanatory power to adjusted R2 = 0.597, with BDI being the most significant predictor of variability in HRQL (adjusted R2 = 0.582; P < 0.001), followed by “Satisfaction with the explanation of the condition at diagnosis” and “Current feelings of optimism” (both P < 0.05). These factors, in addition to disease severity and medication, explain 59.7% of the variability in HRQL across the population. In conclusion, depression (as measured by the BDI) in PD, “satisfaction with the explanation of the condition at diagnosis” and “current feelings of optimism” have a significant impact on HRQL. The completion of this initial analysis is the first step towards developing management guidelines that truly influence the HRQL of patients with PD. © 2001 Movement Disorder Society.

Ancillary